A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Case Comprehensive Cancer Center